LivaNova PLC
LIVN
Rangering i aksjer
#3853
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Aksjekurs
$78.59
Markedsverdi
$4.32B
Endring (1 dag)
-1.40%
Endring (1 år)
43.65%
Land
GB
Handel LivaNova PLC (LIVN)
Kategori
Healthcare
Inntekter for LivaNova PLC (LIVN)
Inntekter i Jun 2026 TTM: $106.69M
Ifølge LivaNova PLC sine nyeste økonomiske rapporter er selskapets nåværende resultat $106.69M. I 2023 hadde selskapet et resultat på $-81.33M, en nedgang sammenlignet med resultatet i 2022, som var $-75.20M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for LivaNova PLC fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $106.69M | 20.81% |
| 2024 | $88.31M | -208.58% |
| 2023 | $-81.33M | 8.16% |
| 2022 | $-75.20M | -39.66% |
| 2021 | $-124.62M | -64.22% |
| 2020 | $-348.29M | 172.89% |
| 2019 | $-127.63M | -48.41% |
| 2018 | $-247.40M | -304.29% |
| 2017 | $121.10M | -466.97% |
| 2016 | $-33.00M | -136.96% |
| 2015 | $89.29M | 11.79% |
| 2014 | $79.88M | 6.12% |
| 2013 | $75.27M | 24.58% |
| 2012 | $60.42M | 24.16% |
| 2011 | $48.66M | 26.44% |
| 2010 | $38.49M | 40.21% |
| 2009 | $27.45M | -358.97% |
| 2008 | $-10.60M | -79.26% |
| 2007 | $-51.10M | -13.34% |
| 2006 | $-58.97M | 383.67% |
| 2005 | $-12.19M | -274.42% |
| 2004 | $6.99M | 31.53% |
| 2003 | $5.31M | -119.60% |
| 2002 | $-27.12M | 412.06% |
| 2000 | $-5.30M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $7.51B | 6,940.15% |
US
|
|
| $5.56B | 5,114.27% |
IE
|
|
| $5.15B | 4,725.28% |
US
|
|
| $3.86B | 3,518.96% |
US
|
|
| - | - |
DE
|
